Viking Therapeutics VKTX Proceeds from exercises of stock options and other stock issuances

Proceeds from exercises of stock options and other stock issuances at other companies

Arcus BiosciencesRCUS

——

BioCryst PharmaceuticalsBCRX

——

Mirum Pharmaceuticals, Inc.MIRM

——

Revenue-—

Operating income-$164.1M-196%

Net income-$158.3M-247%

EPS (diluted)-$1.37-234%

Cash & equivalents$118.1M+211%

Total debt$137.0K-87.8%

Total equity$501.9M-40.7%

Total assets$608.2M-29.8%

Operating cash flow-$114.0M-118%

Market cap$4.04B+38.7%

Return on equity-70%-94.5pp

Debt / equity0×0.0×

Current ratio5.7×-38.5×

Reported directly by Viking Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.

The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Viking Therapeutics's proceeds from exercises of stock options and other stock issuances?: Viking Therapeutics (VKTX) reported proceeds from exercises of stock options and other stock issuances of $450K in Q1 2026.
How has Viking Therapeutics's proceeds from exercises of stock options and other stock issuances changed year-over-year?: Viking Therapeutics's proceeds from exercises of stock options and other stock issuances increased by 28.9% year-over-year, from $349K to $450K.